Morges, Switzerland (14 January 2026): Jazz Pharmaceuticals has selected Kainjoo, the Switzerland-based brand-tech network specialising in regulated industries, to design and deliver an analytics scorecard programme supporting the digital performance governance of its Global Medical Affairs (GMA) portal.
- Kainjoo defined a Key Performance Indicator (KPI) framework to track acquisition, engagement, retention and reputation across Jazz’s GMA digital properties.
- The scorecard supports Jazz’s medical affairs engagement with US healthcare professionals (HCPs).
- The model is engineered to scale across therapeutic areas, personas and lifecycle events, with adoption and governance built into the handover.
Jazz Pharmaceuticals operates a global medical affairs portal that serves US HCPs across its therapeutic areas. The brief asked for a measurement framework that leadership teams could use repeatedly to make sharper decisions, faster, without fragmenting reporting across stakeholders, agencies or business units.
Kainjoo’s response paired strategic consulting with operational delivery. The team ran working sessions with Jazz to surface the constraints of the existing analytics stack, then built a scorecard tailored to those constraints. The framework structures measurement across reach, organic visibility, earned-media reputation, on-platform engagement and retention, with a shared definitions layer that makes every term auditable for medical, regulatory and commercial reviewers.
“Jazz needed a scorecard that leadership teams can use repeatedly to make sharper decisions, faster,” said Haider Alleg, Founder of Kainjoo. “The outcome is a pragmatic framework that clarifies what to measure, why it matters, and how to scale measurement without sacrificing governance. It is built to fit alongside the existing analytics stack and to extend cleanly into dashboards, alerting and tagging standards over time.”
The engagement highlights include a scorecard model tailored to Jazz’s constraints and stakeholder needs, a KPI framework to support consistent reporting and decision-making, and an adoption and scalability analysis to ensure the scorecard can evolve across properties, personas and lifecycle events. The programme is designed to be implemented alongside Jazz’s existing analytics and reporting infrastructure and can be extended into operational dashboards, alerting and tagging standards as the GMA portal matures.
Kainjoo and Jazz are making interview opportunities available to accredited media on request.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. Its portfolio spans neuroscience and oncology and is supported by a commitment to scientific innovation and measurable patient impact.
About Kainjoo
Kainjoo is a Swiss marketing and consulting network founded in 2015 and headquartered in Morges. The firm works at the intersection of life sciences, analytics and brand-tech, helping pharmaceutical, medical and healthcare organisations turn digital activity into measurable performance. Its medical-affairs and HCP-engagement practice is built around measurement frameworks, governance models and operating systems that hold up to clinical, regulatory and commercial review — and that scale across therapeutic areas, geographies and partner ecosystems.
For media inquiries, please contact:
Haider Alleg, Founder
press@kainjoo.com
+41 21 561 34 96
www.kainjoo.com
